JP2019123731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019123731A5 JP2019123731A5 JP2019061398A JP2019061398A JP2019123731A5 JP 2019123731 A5 JP2019123731 A5 JP 2019123731A5 JP 2019061398 A JP2019061398 A JP 2019061398A JP 2019061398 A JP2019061398 A JP 2019061398A JP 2019123731 A5 JP2019123731 A5 JP 2019123731A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- pharmaceutically acceptable
- composition
- mci
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 239000013522 chelant Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000003039 myelosuppressive effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887603P | 2013-10-07 | 2013-10-07 | |
| US61/887,603 | 2013-10-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521278A Division JP6787781B2 (ja) | 2013-10-07 | 2014-10-07 | 高純度治療用骨剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019123731A JP2019123731A (ja) | 2019-07-25 |
| JP2019123731A5 true JP2019123731A5 (enExample) | 2020-02-20 |
| JP7068222B2 JP7068222B2 (ja) | 2022-05-16 |
Family
ID=52813560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521278A Active JP6787781B2 (ja) | 2013-10-07 | 2014-10-07 | 高純度治療用骨剤 |
| JP2019061398A Active JP7068222B2 (ja) | 2013-10-07 | 2019-03-27 | 高純度治療用骨剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521278A Active JP6787781B2 (ja) | 2013-10-07 | 2014-10-07 | 高純度治療用骨剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10172965B2 (enExample) |
| EP (1) | EP3054996B1 (enExample) |
| JP (2) | JP6787781B2 (enExample) |
| CA (1) | CA2926652C (enExample) |
| DK (1) | DK3054996T3 (enExample) |
| ES (1) | ES2949277T3 (enExample) |
| FI (1) | FI3054996T3 (enExample) |
| HU (1) | HUE062439T2 (enExample) |
| PL (1) | PL3054996T3 (enExample) |
| PT (1) | PT3054996T (enExample) |
| SI (1) | SI3054996T1 (enExample) |
| WO (1) | WO2015054173A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11369700B2 (en) * | 2015-05-25 | 2022-06-28 | IGL Pharma Inc. | DOTMP kit formulations for radioisotopes |
| WO2016191413A1 (en) | 2015-05-25 | 2016-12-01 | Iso Therapeutics Group, Llc | Dotmp kit formulations for radioisotopes |
| US11813339B2 (en) * | 2017-02-08 | 2023-11-14 | Igl Pharma, Inc. | Method of use for therapeutic bone agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898724A (en) | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
| US5064633A (en) | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
| US5059412A (en) | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
| US4882142A (en) * | 1988-12-19 | 1989-11-21 | The Dow Chemical Company | Bone marrow suppressing agents |
| MC2260A1 (fr) | 1990-06-18 | 1993-04-26 | Dow Chemical Co | Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation |
| CA2371728C (en) * | 1999-06-11 | 2009-06-02 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| US7045116B2 (en) * | 2001-12-13 | 2006-05-16 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
| EP1556088A2 (en) | 2002-10-29 | 2005-07-27 | Engene, Inc. | Compositions for cancer treatment |
| US20040258614A1 (en) * | 2003-06-20 | 2004-12-23 | University Of Maryland, Baltimore | Microparticles for microarterial imaging and radiotherapy |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| JP5199108B2 (ja) | 2005-11-14 | 2013-05-15 | ユニヴァーシティー オブ サザン カリフォルニア | インテグリン結合小分子 |
| WO2011149844A1 (en) * | 2010-05-24 | 2011-12-01 | Iso Therapeutics Group Llc | Delivery of high dose therapeutic radioisotopes to bone |
-
2014
- 2014-10-07 SI SI201432033T patent/SI3054996T1/sl unknown
- 2014-10-07 ES ES14852866T patent/ES2949277T3/es active Active
- 2014-10-07 CA CA2926652A patent/CA2926652C/en active Active
- 2014-10-07 US US15/027,280 patent/US10172965B2/en active Active
- 2014-10-07 PT PT148528664T patent/PT3054996T/pt unknown
- 2014-10-07 JP JP2016521278A patent/JP6787781B2/ja active Active
- 2014-10-07 DK DK14852866.4T patent/DK3054996T3/da active
- 2014-10-07 PL PL14852866.4T patent/PL3054996T3/pl unknown
- 2014-10-07 HU HUE14852866A patent/HUE062439T2/hu unknown
- 2014-10-07 FI FIEP14852866.4T patent/FI3054996T3/fi active
- 2014-10-07 WO PCT/US2014/059385 patent/WO2015054173A1/en not_active Ceased
- 2014-10-07 EP EP14852866.4A patent/EP3054996B1/en active Active
-
2018
- 2018-11-17 US US16/194,324 patent/US10596277B2/en active Active
-
2019
- 2019-03-27 JP JP2019061398A patent/JP7068222B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2915005C (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
| ES2212580T3 (es) | Inhibidores de la proteina farnesil-transferasa para el tratamiento de artropatias. | |
| EP1244434B1 (de) | Verwendung von chemotherapeutika zur topischen behandlung | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2020033360A5 (enExample) | ||
| JP2019123731A5 (enExample) | ||
| SE9901573D0 (sv) | New compounds | |
| ZA202107431B (en) | Para-aminohippuric acid (pah) as a renal protective substance | |
| RU2020107416A (ru) | Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака | |
| KR102732030B1 (ko) | 아리피프라졸 주사가능한 제제의 투여 방법 | |
| JP2016516773A5 (enExample) | ||
| JP2015528501A5 (enExample) | ||
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| CL2024001520A1 (es) | Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales | |
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| CO2022008730A2 (es) | Composición farmacéutica para el tratamiento de la enfermedad vascular pulmonar y/o disfunción cardíaca en pacientes paliados con fontan | |
| RU2017140078A (ru) | Косметический способ и его терапевтическое применение для уменьшения объема жировой ткани | |
| SE9901572D0 (sv) | New compounds | |
| JPWO2008075706A1 (ja) | 間質性肺炎治療剤 | |
| JP2019535830A5 (enExample) | ||
| WO2014210369A2 (en) | Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents | |
| US4847299A (en) | Use of 15-deoxyspergualine as a pharmaceutical | |
| JP2000507207A (ja) | 複合注射剤 | |
| TW202220650A (zh) | 5-甲基-1,2,4-噁二唑-3-基化合物之低劑量療法及調配物 |